Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Long-Term Follow-up of Survival in Hodgkin's Lymphoma | NEJM
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
Clinical Trial Endpoints for Oncology Studies
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink
Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. - Abstract - Europe PMC
Early Stage W.H.O. Grade I and II Follicular Lymphoma Treated with Radiation Therapy Alone | PLOS ONE
A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma | BMC Cancer | Full Text
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study | British Journal of Cancer
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Worse event-free and relapse-free survival in financially disadvantaged patients with breast cancer in South India - ScienceDirect
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
When Overall Survival Fails to Confirm Event-Free Survival, Should the Latter Be Used to Set the Standard of Care? | Journal of Clinical Oncology
Educational Sessions: "Approving new therapies for early breast cancer" - YouTube
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433 | Haematologica
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review | Leukemia
Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching | PLOS ONE
Kaplan-Meier curves for (A) event-free survival and (B) | Open-i
